Noopept: (Ноопепт, N-phenylacetyl-L-prolylglycine ethyl ester, GVS-111) is a modern synthetic nootropic compound developed in Russia in the 1980s, currently manufactured by Lekko Pharmaceuticals. Noopept demonstrated wide spectrum of cognition improving effects as well as pronounced neuroprotective activities both in vivo and in vitro conditions. Compared to piracetam GVS-111 produces a cognition enhancing effect at much lower concentrations and demonstrates activity over a wider range of cognition disturbances and neuronal damages. Now GVS-111 is sold without a prescription in Russia (as nootropic suplement). Noopept is useful for improving cognitive deficits, and may be especially useful for researchers investigating neurodegeneration induced by conditions like Alzheimer’s and Parkinson’s disease.
Noopept Dosage and Administration: The standard dose for orally ingested Noopept is 10 mg – 30 mg (3 times a day). This dose is much lower than the typical dose for Piracetam, which is about 4800 mg. It means that GVS-111 is about 1000 times more potent than Piracetam.
Memory, Learning and Focus: GVS-111 interacts with a number of neurotransmitters inside the brain that can increase your brain energy in regards to memory and learning. Based on research, Noopept can boost overall performance in all of the 3 elements of memory that include development, access and recovery.
Decreased level of cytokines (inflammatory molecules)
Decreased hyperglycemia, BMI, pain sensitivity
Decreased oxidative stress, glutamate toxicity
References:
Dipeptide Piracetam Analogue Noopept Improves Viability of Hippocampal HT-22 Neurons in the Glutamate Toxicity Model. Antipova TA, Nikolaev SV, Ostrovskaya PU, Gudasheva TA, Seredenin SB. Bull Exp Biol Med. 2016 May;161(1):58-60. doi: 10.1007/s10517-016-3344-z. Epub 2016 Jun 6.
Molecular Mechanism Underlying the Action of Substituted Pro-Gly Dipeptide Noopept. Vakhitova YV, Sadovnikov SV, Borisevich SS, Ostrovskaya RU, A Gudasheva T, Seredenin SB. Acta Naturae. 2016 Jan-Mar;8(1):82-9.
Nootropic dipeptide noopept enhances inhibitory synaptic transmission in the hippocampus. Povarov IS, Kondratenko RV, Derevyagin VI, Ostrovskaya RU, Skrebitskii VG. Bull Exp Biol Med. 2015 Jan;158(3):349-51. doi: 10.1007/s10517-015-2759-2. Epub 2015 Jan 9.
Neuroprotective effect of novel cognitive enhancer noopept on AD-related cellular model involves the attenuation of apoptosis and tau hyperphosphorylation. Ostrovskaya RU, Vakhitova YV, Kuzmina USh, Salimgareeva MKh, Zainullina LF, Gudasheva TA, Vakhitov VA, Seredenin SB. J Biomed Sci. 2014 Aug 6;21:74. doi: 10.1186/s12929-014-0074-2.
An experimental study of the anti-inflammatory action of noopept and its effect on the level of cytokines. Alekseeva SV, Kovalenko LP, Tallerova AV, Gudasheva TA, Durnev AD. Eksp Klin Farmakol. 2012;75(9):25-7.
Neuroprotective and nootropic drug noopept rescues α-synuclein amyloid cytotoxicity. Jia X, Gharibyan AL, Öhman A, Liu Y, Olofsson A, Morozova-Roche LA. J Mol Biol. 2011 Dec 16;414(5):699-712. doi: 10.1016/j.jmb.2011.09.044. Epub 2011 Oct 1.
